ALKBH5 and neoplasm: In conclusion, this study successfully utilized NGR-modified BNVs to deliver ALKBH5 siRNA, reversing immunotherapy resistance in OC, significantly inhibiting tumor growth and metastasis, and enhancing anti-tumor immune responses by modulating the TIME.